The Impact of Age and Severity of Attention Deficit Hyperactivity Disorder (ADHD) Before COVID-19 on the Severity of ADHD During the COVID-19 Lockdowns, as Reported by the Mothers.

IF 1.5 4区医学 Q4 CLINICAL NEUROLOGY Clinical Neuropharmacology Pub Date : 2025-05-01 Epub Date: 2025-03-05 DOI:10.1097/WNF.0000000000000632

Pavel Golubchik, Abraham Weizman

{"title":"The Impact of Age and Severity of Attention Deficit Hyperactivity Disorder (ADHD) Before COVID-19 on the Severity of ADHD During the COVID-19 Lockdowns, as Reported by the Mothers.","authors":"Pavel Golubchik, Abraham Weizman","doi":"10.1097/WNF.0000000000000632","DOIUrl":null,"url":null,"abstract":"Objectives: This cohort study aimed to better understand the relationship between attention deficit hyperactivity disorder (ADHD) severity predating the COVID-19 outbreak, in children with ADHD, and the severity of ADHD symptoms during the COVID-19 lockdowns.Methods: Age and clinical data, including ADHD-Rating Scale scores, of 30 children and adolescents with ADHD, aged 7-18 years, were collected from medical files, for the 6-month period that predated the COVID-19 outbreak. During the COVID-19 lockdowns, the children's ADHD severity was evaluated by the mothers using the Clinical Global Impression-Severity scale (CGI-S). The correlations of CGI-S scores with age and above-mentioned ADHD-Rating Scale scores that were collected before COVID-19 were then assessed.Results: Significant correlation was found between age of participants and CGI-S scores ( P = 0.034). Additionally, participants who continued ADHD pharmacological treatment ( P = 0.02) and used remote clinical treatment ( P = 0.008) demonstrated lower mother reported CGI-S scores.Conclusions: In children with ADHD, younger age, ongoing stimulant-treatment and ongoing remote visits with a caretaker, seem to correlate with lower ADHD-symptom severity during COVID-19 lockdowns.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"86-88"},"PeriodicalIF":1.5000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000632","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/5 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This cohort study aimed to better understand the relationship between attention deficit hyperactivity disorder (ADHD) severity predating the COVID-19 outbreak, in children with ADHD, and the severity of ADHD symptoms during the COVID-19 lockdowns.

Methods: Age and clinical data, including ADHD-Rating Scale scores, of 30 children and adolescents with ADHD, aged 7-18 years, were collected from medical files, for the 6-month period that predated the COVID-19 outbreak. During the COVID-19 lockdowns, the children's ADHD severity was evaluated by the mothers using the Clinical Global Impression-Severity scale (CGI-S). The correlations of CGI-S scores with age and above-mentioned ADHD-Rating Scale scores that were collected before COVID-19 were then assessed.

Results: Significant correlation was found between age of participants and CGI-S scores ( P = 0.034). Additionally, participants who continued ADHD pharmacological treatment ( P = 0.02) and used remote clinical treatment ( P = 0.008) demonstrated lower mother reported CGI-S scores.

Conclusions: In children with ADHD, younger age, ongoing stimulant-treatment and ongoing remote visits with a caretaker, seem to correlate with lower ADHD-symptom severity during COVID-19 lockdowns.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

母亲报告的COVID-19前注意缺陷多动障碍（ADHD）的年龄和严重程度对COVID-19封锁期间ADHD严重程度的影响

目的：本队列研究旨在更好地了解COVID-19爆发前ADHD儿童的注意缺陷多动障碍（ADHD）严重程度与COVID-19封锁期间ADHD症状严重程度之间的关系。方法：从医疗档案中收集30例7-18岁ADHD儿童和青少年的年龄和临床资料，包括ADHD评定量表得分，时间为COVID-19爆发前6个月。在COVID-19封锁期间，母亲使用临床总体印象严重程度量表（CGI-S）评估儿童的ADHD严重程度。然后评估CGI-S评分与年龄的相关性以及COVID-19前收集的上述adhd评定量表评分。结果：受试者年龄与CGI-S评分有显著相关（P = 0.034）。此外，继续ADHD药物治疗（P = 0.02）和使用远程临床治疗（P = 0.008）的参与者表现出较低的母亲报告的CGI-S评分。结论：在患有ADHD的儿童中，年龄较小、正在进行兴奋剂治疗和正在与看护人进行远程访问似乎与COVID-19封锁期间较低的ADHD症状严重程度相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Neuropharmacology 医学-临床神经学

CiteScore

1.20

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.